Literature DB >> 1082452

Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations.

R Tung, R Silber, F Quagliata, M Conklyn, J Gottesman, R Hirschhorn.   

Abstract

The level, phenotypes, and isozyme distribution of adenosine deaminase (ADA) were determined in lymphocytes from patients with chronic lymphocytic leukemia (CLL). The ADA level in lymphocytes from patients with untreated CLL was consistently lower than in lymphocytes from normal subjects. No significant differences were found in the phenotype or isozyme distribution. In untreated patients, the ADA level was inversely correlated with the lymphocyte count and the percentage of bursa-equivalent (B) cells. After therapy, a diminution in the lymphocyte count was associated with an increase of ADA activity towards normal levels. The ADA levels were slightly higher in the thymus-derived (T) than in the B lymphocytes from normal subjects. The B cells had lower activity than T cells in patients with CLL. They also had a lower activity than the B cells from normal subjects. The ADA level was 2.3-fold higher in T cells from patients with CLL than in normal T cells. The decrease in ADA levels is an anomaly that is reversible and appears to be a reflection of the proliferation of abnormal B cells in this disorder.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1082452      PMCID: PMC436711          DOI: 10.1172/JCI108334

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Serum proteins in leukemia.

Authors:  R W RUNDLES; E V COONRAD; T ARENDS
Journal:  Am J Med       Date:  1954-06       Impact factor: 4.965

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Studies in chronic lymphocytic leukemia: further studies of the proliferative abnormality of the blood lymphocyte.

Authors:  A D Rubin; K Havemann; W Dameshek
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

6.  Lymphocyte plasma membranes: analysis of proteins and glycoproteins by SDS-gel electrophoresis.

Authors:  J Lopes; M Nachbar; D Zucker-Franklin; R Silber
Journal:  Blood       Date:  1973-01       Impact factor: 22.113

7.  Adenosine deaminase isozymes in human tissues.

Authors:  Y H Edwards; D A Hopkinson; H Harris
Journal:  Ann Hum Genet       Date:  1971-10       Impact factor: 1.670

8.  Severe combined immunodeficiency and adenosine deaminase deficiency.

Authors:  R Parkman; E W Gelfand; F S Rosen; A Sanderson; R Hirschhorn
Journal:  N Engl J Med       Date:  1975-04-03       Impact factor: 91.245

9.  Further data on the adenosine deaminase (ADA) polymprphism and a report of a new phenotype.

Authors:  D A Hopkinson; P J Cook; H Harris
Journal:  Ann Hum Genet       Date:  1969-05       Impact factor: 1.670

10.  Decreased lymphocyte adenosine deaminase activity in acute lymphocytic leukemia children and their parents.

Authors:  J Zimmer; A S Khalifa; J J Lightbody
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

View more
  25 in total

1.  Adenosine deaminase activity in erythrocytes, lymphocytes, polymorphonuclear neutrophil leucocytes and cultured cells: a possible role in the immune response.

Authors:  A Adams; R A Harkness; J G McVie
Journal:  J Inherit Metab Dis       Date:  1978       Impact factor: 4.982

2.  Adenosine deaminase activity in thymus and other human tissues.

Authors:  A Adams; R A Harkness
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

3.  A novel transition state analog inhibitor of guanase based on azepinomycin ring structure: Synthesis and biochemical assessment of enzyme inhibition.

Authors:  Saibal Chakraborty; Niti H Shah; James C Fishbein; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2010-11-27       Impact factor: 2.823

4.  Adenosine deaminase activity in relation to the appearance of early and late Epstein-Barr virus antigens induced in lymphoblastoid cells.

Authors:  M Margalith; I Hendler
Journal:  Mol Cell Biochem       Date:  1991-12-11       Impact factor: 3.396

5.  Repeated pentostatin (2'deoxycoformycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia.

Authors:  R O Dillman; A L Yu; C N Qiao
Journal:  West J Med       Date:  1988-03

6.  Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Authors:  J F Smyth; D G Poplack; B J Holiman; B G Leventhal; G Yarbro
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

7.  Adenosine deaminase and nucleoside phosphorylase activities in normal human blood mononuclear cell subpopulations.

Authors:  R P MacDermott; G L Tritsch; J F Formeister
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

8.  Alteration of adenosine deaminase levels in peripheral blood lymphocytes of patients with gastric cancer.

Authors:  O Kojima; T Majima; Y Uehara; T Yamane; Y Fujita; T Takahashi; S Majima
Journal:  Jpn J Surg       Date:  1985-03

9.  Synthesis of DNA and poly(adenosine diphosphate ribose) in normal and chronic lymphocytic leukemia lymphocytes.

Authors:  N A Berger; J W Adams; G W Sikorski; S J Petzold; W T Shearer
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

10.  Canine cyclic hematopoiesis is associated with abnormal purine and pyrimidine metabolism.

Authors:  W R Osborne; W P Hammond; D C Dale
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.